This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
jie lin
China Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Colon adenocarcinoma (COAD) is the third leading cause of cancer-related death. Although surgical treatment and chemotherapy of COAD have made significant progress, its immunotherapy also has great potential, nowadays.
Methods
Gene expression profiles and clinical data of COAD patients were obtained from The Cancer Genome Atlas_Colon Adenocarcinoma (TCGA_COAD) and Gene Expression Omnibus (GEO) databases, which were further detected for immune-related genes. Immune-related genes were downloaded from Immunology Database and Analysis Portal (ImmPort). LASSO Cox regression analysis was utilized to analyze the immune-related prognostic signature. The prognostic value of the signature was validated by ROC curve. To further detected the potential pathway about immune-related genes in COAD patients, Gene Set Enrichment Analysis (GESA) was used to identify the most significant pathways.
Results
Finally, a total of 436 immune-related mRNA were identified. Eleven prognosis-related genes were selected to establish an immune-related prognostic signature, which divided patients into high and low risk groups. Several biological processes, such as immune response was enriched. Moreover, our prognosis model has better performance in predicting the 1-, 3-, 5- and 8-years overall survival (OS) for patients from the TCGA and GEO cohort. Also, the complicated signature obtained by combining immune-related signatures with clinical factors provides a more accurate OS predicting compared with individual molecular signatures.
Conclusion
We have established a prognostic signature consisting of 11 immune-related genes, which may be potential biomarkers for identifying COAD with a high risk of death. Then, the possibility including immunotherapy in personalized COAD treatment was evaluated.
Keywords
immune, colon adenocarcinoma, prognosis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
jie lin
China Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Colon adenocarcinoma (COAD) is the third leading cause of cancer-related death. Although surgical treatment and chemotherapy of COAD have made significant progress, its immunotherapy also has great potential, nowadays.
Methods
Gene expression profiles and clinical data of COAD patients were obtained from The Cancer Genome Atlas_Colon Adenocarcinoma (TCGA_COAD) and Gene Expression Omnibus (GEO) databases, which were further detected for immune-related genes. Immune-related genes were downloaded from Immunology Database and Analysis Portal (ImmPort). LASSO Cox regression analysis was utilized to analyze the immune-related prognostic signature. The prognostic value of the signature was validated by ROC curve. To further detected the potential pathway about immune-related genes in COAD patients, Gene Set Enrichment Analysis (GESA) was used to identify the most significant pathways.
Results
Finally, a total of 436 immune-related mRNA were identified. Eleven prognosis-related genes were selected to establish an immune-related prognostic signature, which divided patients into high and low risk groups. Several biological processes, such as immune response was enriched. Moreover, our prognosis model has better performance in predicting the 1-, 3-, 5- and 8-years overall survival (OS) for patients from the TCGA and GEO cohort. Also, the complicated signature obtained by combining immune-related signatures with clinical factors provides a more accurate OS predicting compared with individual molecular signatures.
Conclusion
We have established a prognostic signature consisting of 11 immune-related genes, which may be potential biomarkers for identifying COAD with a high risk of death. Then, the possibility including immunotherapy in personalized COAD treatment was evaluated.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Loading...